Search

Author/Creator Behringer, D.M.

1. 36LBA Pathological response to neoadjuvant 5-FU, oxaliplatin and docetaxel (FLOT) versus epirubicin, cisplatin and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO. Issue 3 (September 2015)

Authors:
Pauligk, C.; Tannapfel, A.; Meiler, J.; Luley, K.B.; Kopp, H.G.; Homann, N.; Hofheinz, R.D.; Schmalenberg, H.; Probst, S.; Haag, G.M.; Egger, M.; Behringer, D.M.; Stoehlmacher, J.; Prasnikar, N.; Block, A.; Trojan, J.; Folprecht, G.; Pohl, M.; Schirmacher, P.; Al-Batran, S.E.
Journal:
European journal of cancer
Issue:
Volume 51:Issue 3(2015:Feb.)
Page Start:
S728
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search